Glycogen synthase kinase-3 inhibitors reverse deficits in long-term potentiation and cognition in fragile X mice.
about
A new look at an old drug: neuroprotective effects and therapeutic potentials of lithium saltsDysregulation and restoration of translational homeostasis in fragile X syndromeEmerging pharmacologic treatment options for fragile X syndromeTargeted pharmacological treatment of autism spectrum disorders: fragile X and Rett syndromesTherapeutic Strategies in Fragile X Syndrome: From Bench to Bedside and BackWnt signaling networks in autism spectrum disorder and intellectual disabilityAntipurinergic therapy corrects the autism-like features in the Fragile X (Fmr1 knockout) mouse model.Spaced training rescues memory and ERK1/2 signaling in fragile X syndrome model mice.Delineating the Common Biological Pathways Perturbed by ASD's Genetic Etiology: Lessons from Network-Based StudiesLithium: a promising treatment for fragile X syndrome.Fragile X targeted pharmacotherapy: lessons learned and future directions.Increased long-term potentiation at medial-perforant path-dentate granule cell synapses induced by selective inhibition of histone deacetylase 3 requires Fragile X mental retardation proteinPDE-4 inhibition rescues aberrant synaptic plasticity in Drosophila and mouse models of fragile X syndromeIdentification of fragile X syndrome specific molecular markers in human fibroblasts: a useful model to test the efficacy of therapeutic drugs.Impairments in cognition and neural precursor cell proliferation in mice expressing constitutively active glycogen synthase kinase-3.Functional and structural deficits at accumbens synapses in a mouse model of Fragile X.Lentiviral silencing of GSK-3β in adult dentate gyrus impairs contextual fear memory and synaptic plasticity.Molecular mechanisms regulating impaired neurogenesis of fragile X syndrome human embryonic stem cells.MDM2 inhibition rescues neurogenic and cognitive deficits in a mouse model of fragile X syndromeNeurocognitive endophenotypes in CGG KI and Fmr1 KO mouse models of Fragile X-Associated disorders: an analysis of the state of the fieldIntranasal siRNA administration reveals IGF2 deficiency contributes to impaired cognition in Fragile X syndrome mice.Glycogen synthase kinase-3 inhibitors: Rescuers of cognitive impairments.Glycogen synthase kinase-3 as a therapeutic target for cognitive dysfunction in neuropsychiatric disorders.Glycogen synthase kinase-3 (GSK3): regulation, actions, and diseasesGSK-3β deletion in dentate gyrus excitatory neuron impairs synaptic plasticity and memory.Pharmacotherapy for Fragile X Syndrome: Progress to Date.Glycogen synthase kinase 3 (GSK-3) inhibitors: a patent update (2014-2015).Age-Dependent Long-Term Potentiation Deficits in the Prefrontal Cortex of the Fmr1 Knockout Mouse Model of Fragile X Syndrome.GSK3β Hyperactivity during an Early Critical Period Impairs Prefrontal Synaptic Plasticity and Induces Lasting Deficits in Spine Morphology and Working Memory.Reduced Levels of the Synaptic Functional Regulator FMRP in Dentate Gyrus of the Aging Sprague-Dawley Rat.Alterations in CA1 hippocampal synapses in a mouse model of fragile X syndrome.Microarray analysis of gene expression in the cyclooxygenase knockout mice - a connection to autism spectrum disorder.Assistive technology to promote occupation and reduce mouthing by three boys with fragile X syndrome.Cotinine administration improves impaired cognition in the mouse model of Fragile X syndrome.GSK-3β inhibitor TDZD-8 reduces neonatal hypoxic-ischemic brain injury in mice.GSK3 activity regulates rhythms in hippocampal clock gene expression and synaptic plasticity.Disparate Effects of Lithium and a GSK-3 Inhibitor on Neuronal Oscillatory Activity in Prefrontal Cortex and Hippocampus.A unique type of GSK-3 inhibitor brings new opportunities to the clinic.Endoplasmic reticulum stress induces spatial memory deficits by activating GSK-3.Of Men and Mice: Modeling the Fragile X Syndrome.
P2860
Q26741164-32513366-2774-46F8-B62E-D5AD02D13AFFQ26782616-B7EF6321-4E54-4582-94BD-C56014EC7B4DQ26829152-8A646034-9FEA-4CF7-9111-511CFB4301D6Q27023257-8B666CA5-373D-4A75-99E7-6237CF0305A5Q27337360-8B7F54AD-F53F-40FF-A7B1-582028E8DD3AQ28074740-EC8EF59B-AD8E-4285-A4D9-86FA2B0EE796Q30418368-9952696F-435F-45A0-BC7D-C731DC5A0060Q30603928-C51E7231-02DF-4800-93AB-123B1ECB04BEQ33624758-E100AF91-0CE7-421D-924F-E4D9BB319572Q33777951-45B70B82-5C36-4B36-BC40-3C8ACE24BDA5Q33785983-AF99988C-84E9-4AFC-95DC-CD97A6CA5114Q34563831-F4ADEB7B-29E3-45FB-9D56-4CB1E884C450Q34869830-A7853027-8CB8-4872-B437-84C424D5DEFDQ34871401-7B2A3073-7D74-42E6-92F2-1A17789874AAQ35146005-031EA2F7-AAEE-4CED-9DA0-A7DA9431770BQ35218838-C75A153B-A1AA-4029-A013-2D42B29C1631Q35768941-40330FC3-B646-446E-B019-8F3FB50B6996Q36141229-919749B5-9775-4E04-A921-E409613507B4Q37198789-F1F6EBBA-1075-47A6-B96E-5D316B68DA6AQ37623407-B430D4A9-BBDA-4E16-9834-EE94573A6D89Q37711788-A856E7CA-3D01-4F86-B115-C5F114325F96Q38126701-18D98A4B-90C8-4232-B882-35F595EEBD3EQ38266162-013CDD72-FFAE-45AB-B78D-730A40832F2CQ38272835-2B07445E-3ABF-45F0-9CED-671EC1AC82D7Q38673149-9BB3E448-35B1-411F-82AF-910BB2EC10FFQ38726962-2C628DD4-853A-4567-898D-791F6CFAD263Q39003757-0B30C662-0751-4CF3-88C2-E77F749939FDQ41270458-50FE5453-F7D0-460C-BB6F-E8EBF530AB09Q44693159-65C19373-B4A9-449A-BBCB-1E8689764F01Q47149513-F796137C-9628-4293-BA38-B5EA3CCD15DAQ47255421-C0753D76-DF15-4647-A96B-8E558564AAB0Q47378227-2E6A8FD2-375D-4A59-8FBF-385427C395B9Q47779104-CC626467-ED70-43D7-9E18-66880F9073EDQ47903798-660FC0F2-CB23-4082-8DC4-DCFF75584622Q48168640-BF955815-2747-4748-B677-6481DCC0356BQ48361958-D48FD55C-FD48-4FC4-B1F5-920CDD3411FAQ49333511-66CF0D27-88E5-462B-8B1A-C5A41899E2B5Q50114697-E93FBDBE-D007-41C9-BD64-0FEEE9F4F185Q52575375-C032BA01-3FF0-4C71-9379-39AB058D4145Q53422584-5C53E51A-8EAD-4785-A92B-9BDE9A11D459
P2860
Glycogen synthase kinase-3 inhibitors reverse deficits in long-term potentiation and cognition in fragile X mice.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 13 September 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Glycogen synthase kinase-3 inh ...... d cognition in fragile X mice.
@en
Glycogen synthase kinase-3 inh ...... d cognition in fragile X mice.
@nl
type
label
Glycogen synthase kinase-3 inh ...... d cognition in fragile X mice.
@en
Glycogen synthase kinase-3 inh ...... d cognition in fragile X mice.
@nl
prefLabel
Glycogen synthase kinase-3 inh ...... d cognition in fragile X mice.
@en
Glycogen synthase kinase-3 inh ...... d cognition in fragile X mice.
@nl
P2093
P2860
P1476
Glycogen synthase kinase-3 inh ...... d cognition in fragile X mice.
@en
P2093
Aimee V Franklin
Lori L McMahon
Margaret K King
Richard S Jope
Valle Palomo
P2860
P304
P356
10.1016/J.BIOPSYCH.2013.08.003
P407
P50
P577
2013-09-13T00:00:00Z